PDS Biotechnology (NASDAQ:PDSB – Get Free Report)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a note issued to investors on Monday,Benzinga reports. They currently have a $21.00 price objective on the stock.
Other research analysts also recently issued research reports about the stock. StockNews.com downgraded shares of PDS Biotechnology from a “hold” rating to a “sell” rating in a report on Saturday, November 9th. B. Riley lowered their price objective on shares of PDS Biotechnology from $9.00 to $7.00 and set a “buy” rating on the stock in a report on Monday, November 25th. One research analyst has rated the stock with a sell rating, three have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, PDS Biotechnology presently has a consensus rating of “Moderate Buy” and an average price target of $11.67.
Get Our Latest Stock Report on PDS Biotechnology
PDS Biotechnology Stock Down 0.8 %
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC raised its holdings in shares of PDS Biotechnology by 9.8% in the third quarter. Geode Capital Management LLC now owns 415,113 shares of the company’s stock valued at $1,586,000 after purchasing an additional 37,142 shares during the last quarter. Blair William & Co. IL raised its holdings in shares of PDS Biotechnology by 29.4% in the fourth quarter. Blair William & Co. IL now owns 157,500 shares of the company’s stock valued at $257,000 after purchasing an additional 35,757 shares during the last quarter. Renaissance Technologies LLC raised its holdings in shares of PDS Biotechnology by 331.0% in the fourth quarter. Renaissance Technologies LLC now owns 100,000 shares of the company’s stock valued at $163,000 after purchasing an additional 76,800 shares during the last quarter. XTX Topco Ltd raised its holdings in shares of PDS Biotechnology by 241.8% in the third quarter. XTX Topco Ltd now owns 67,182 shares of the company’s stock valued at $257,000 after purchasing an additional 47,528 shares during the last quarter. Finally, Two Sigma Investments LP raised its holdings in shares of PDS Biotechnology by 273.5% in the fourth quarter. Two Sigma Investments LP now owns 65,732 shares of the company’s stock valued at $107,000 after purchasing an additional 48,132 shares during the last quarter. Institutional investors and hedge funds own 26.84% of the company’s stock.
About PDS Biotechnology
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.
Recommended Stories
- Five stocks we like better than PDS Biotechnology
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Nebius Slides Post-Earnings: A Long-Term Buy Opportunity?
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- NVIDIA Stock: A Market Barometer in Tech’s Turbulent Times
- Growth Investing: Should You Adopt This Investing Strategy in 2022?
- Palantir Stock Nears Bear Market Territory – Why and What’s Next?
Receive News & Ratings for PDS Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PDS Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.